Neurovalens
PrivateLast Round
Debt
Aug 19, 2025
Total Funding Raised
$22.91M
Momentum Score
25 /100
Company Overview
Neurovalens is a health-technology company that develops non-invasive neurostimulation products to address global health issues. The company, founded in 2013, specializes in medical devices that use transdermal electrical stimulation to target key areas of the brain, such as the hypothalamus and brainstem, which regulate metabolic function, stress response, and circadian rhythms. Its products, including the FDA-cleared Modius Sleep for insomnia and Modius Calm for anxiety, offer a drug-free alternative to treatment. Neurovalens is actively engaged in clinical trials for other applications, including treatments for obesity, PTSD, and diabetes. The company is headquartered in Belfast, Northern Ireland, and is expanding its commercial presence in the US and other global markets.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Mental Health, Health IoT
Business Model
B2B2C
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurovalens Comps
Public and private peers based on sector, stage, and business model.
Neurovalens Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Aug 19, 2025 | ||||
| Early Funding | Aug 19, 2025 | ||||
| Series A Extension | Apr 8, 2024 | ||||
| VC Round | Jul 20, 2020 | ||||
| Debt | Oct 24, 2019 | ||||
Grant | Sep 25, 2019 |
Key People
Founding team and executive leadership
Neurovalens Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Angel CoFund | VC Round, Early Funding |
| Future Fund | VC Round |
| British Business Bank | Series A Extension |
| IQ Capital | Series A Extension, Series A, Early Funding, VC Round |
| Investment Fund for Northern Ireland | Early Funding |
| Whiterock's Growth Capital Fund | Early Funding |
| Clarendon Fund Managers | VC Round, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 19, 2025
$8.1M raised in early funding.
- May 23, 2025
Won BVCA Vision 2025 Award for Northern Ireland.
Neurovalens Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neurovalens's valuation, stock price, and market status.
